{"entity":{"id":"javier-cortes","kind":"person","name":"Javier Cortés","aka":[],"tldr":"Breast oncologist who led DESTINY-Breast03 and DESTINY-Breast09, the trials that made Enhertu the HER2-positive standard.","summary":"Javier Cortés is Head of the International Breast Cancer Center (IBCC) in Barcelona, having built his career at Vall d'Hebron University Hospital and VHIO. His specialisms are breast cancer, HER2-positive disease and antibody-drug conjugates. He was principal investigator of DESTINY-Breast03, which compared trastuzumab deruxtecan with trastuzumab emtansine and was reported in the New England Journal of Medicine, and of DESTINY-Breast09, which tested trastuzumab deruxtecan plus pertuzumab in the first line. He also co-led CLEOPATRA and PHERGain. These trials made trastuzumab deruxtecan the HER2-positive standard, and his publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cortes%20J%5BAuthor%5D%20trastuzumab%20deruxtecan"}],"tags":[],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":["her2"],"drugs":["trastuzumab-deruxtecan","pertuzumab","trastuzumab-emtansine"],"companies":[],"institutions":["vall-dhebron"],"pathways":[],"terms":[],"trials":["destiny-breast03","destiny-breast09","cleopatra","phergain"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head, International Breast Cancer Center (IBCC), Barcelona; formerly Vall d'Hebron","institutionId":"vall-dhebron","specialisms":["Breast cancer","HER2-positive disease","Antibody-drug conjugates"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cortes%20J%5BAuthor%5D%20trastuzumab%20deruxtecan"}],"papers":[{"title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer (DESTINY-Breast03)","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2115022"},{"title":"ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2028485","doi":"10.1056/NEJMoa2028485"},{"title":"KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2112651","doi":"10.1056/NEJMoa2112651"},{"title":"monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer","journal":"Journal of Clinical Oncology","year":2020,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=monarchE+abemaciclib+adjuvant+Johnston+2020"}],"orcid":"0000-0001-7623-1583"},"route":"/people/javier-cortes/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"drug":[{"id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"},{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/"}],"institution":[{"id":"vall-dhebron","kind":"institution","name":"Vall d'Hebron University Hospital / VHIO","route":"/institutions/vall-dhebron/"}],"trial":[{"id":"cleopatra","kind":"trial","name":"CLEOPATRA","route":"/trials/cleopatra/"},{"id":"destiny-breast03","kind":"trial","name":"DESTINY-Breast03","route":"/trials/destiny-breast03/"},{"id":"destiny-breast09","kind":"trial","name":"DESTINY-Breast09","route":"/trials/destiny-breast09/"},{"id":"phergain","kind":"trial","name":"PHERGain","route":"/trials/phergain/"}],"paper":[{"id":"paper-ascent-nejm-2021","kind":"paper","name":"ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer","route":"/key-papers/paper-ascent-nejm-2021/"},{"id":"paper-capitello-290-capivasertib-paclitaxel-ann-oncol-2026","kind":"paper","name":"Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial","route":"/key-papers/paper-capitello-290-capivasertib-paclitaxel-ann-oncol-2026/"},{"id":"paper-tropion-breast02-ann-oncol-2026","kind":"paper","name":"Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial","route":"/key-papers/paper-tropion-breast02-ann-oncol-2026/"},{"id":"paper-destiny-breast03-nejm-2022","kind":"paper","name":"DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer","route":"/key-papers/paper-destiny-breast03-nejm-2022/"},{"id":"paper-esmo-metastatic-breast-cancer-guideline-ann-oncol-2021","kind":"paper","name":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","route":"/key-papers/paper-esmo-metastatic-breast-cancer-guideline-ann-oncol-2021/"},{"id":"paper-keynote-522-nejm-2022","kind":"paper","name":"KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer","route":"/key-papers/paper-keynote-522-nejm-2022/"},{"id":"paper-monarche-jco-2020","kind":"paper","name":"monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer","route":"/key-papers/paper-monarche-jco-2020/"}],"roadmap":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/"}]}}